2.50
Hdl Handle:
http://hdl.handle.net/10547/578855
Title:
The innovative evolution of cancer gene and cellular therapies
Authors:
Lam, P.; Khan, Ghazala; Stripecke, R.; Hui, K.M.; Kasahara, N.; Peng, Kah-Whye; Guinn, Barbara-Ann
Abstract:
We provide an overview of the latest developments in cancer gene therapy--from the bench to early-stage clinical trials. We describe the most recent work of worldwide teams including experienced scientists and clinicians, reflecting the recent emergence of gene therapy from the 'Valley of Death'. The treatment efficacy of clinical gene therapy has now been shown in a number of diseases including cancer and we are observing a renewed interest by big pharmaceutical and biotechnology companies most obviously demonstrated by Amgen's acquisition of Biovex for up to USD$1 billion. There is an opportunity to be cautiously hopeful regarding the future of gene therapy in the clinic and we review here some of the most recent progress in the field.
Citation:
Lam, P., Khan, G., Stripecke, R., Hui, K.M., Kasahara, N., Peng, K.-W. & Guinn, B.A (2013) 'The innovative evolution of cancer gene and cellular therapies'. Cancer Gene Therapy, 20 (3) pp141-9
Publisher:
Nature Publishing Group
Journal:
Cancer Gene Therapy
Issue Date:
1-Feb-2013
URI:
http://hdl.handle.net/10547/578855
DOI:
10.1038/cgt.2012.93
Additional Links:
http://www.nature.com/doifinder/10.1038/cgt.2012.93
Type:
Article
Language:
en
ISSN:
0929-1903; 1476-5500
Appears in Collections:
Biomedicine and Nutrition Research Group

Full metadata record

DC FieldValue Language
dc.contributor.authorLam, P.en
dc.contributor.authorKhan, Ghazalaen
dc.contributor.authorStripecke, R.en
dc.contributor.authorHui, K.M.en
dc.contributor.authorKasahara, N.en
dc.contributor.authorPeng, Kah-Whyeen
dc.contributor.authorGuinn, Barbara-Annen
dc.date.accessioned2015-09-29T08:09:02Zen
dc.date.available2015-09-29T08:09:02Zen
dc.date.issued2013-02-01en
dc.identifier.citationLam, P., Khan, G., Stripecke, R., Hui, K.M., Kasahara, N., Peng, K.-W. & Guinn, B.A (2013) 'The innovative evolution of cancer gene and cellular therapies'. Cancer Gene Therapy, 20 (3) pp141-9en
dc.identifier.issn0929-1903en
dc.identifier.issn1476-5500en
dc.identifier.doi10.1038/cgt.2012.93en
dc.identifier.urihttp://hdl.handle.net/10547/578855en
dc.description.abstractWe provide an overview of the latest developments in cancer gene therapy--from the bench to early-stage clinical trials. We describe the most recent work of worldwide teams including experienced scientists and clinicians, reflecting the recent emergence of gene therapy from the 'Valley of Death'. The treatment efficacy of clinical gene therapy has now been shown in a number of diseases including cancer and we are observing a renewed interest by big pharmaceutical and biotechnology companies most obviously demonstrated by Amgen's acquisition of Biovex for up to USD$1 billion. There is an opportunity to be cautiously hopeful regarding the future of gene therapy in the clinic and we review here some of the most recent progress in the field.en
dc.language.isoenen
dc.publisherNature Publishing Groupen
dc.relation.urlhttp://www.nature.com/doifinder/10.1038/cgt.2012.93en
dc.rightsArchived with thanks to Cancer Gene Therapyen
dc.subjectcancer gene therapyen
dc.subjectcancer immunotherapyen
dc.subjectcellular therapyen
dc.titleThe innovative evolution of cancer gene and cellular therapiesen
dc.typeArticleen
dc.identifier.journalCancer Gene Therapyen
All Items in UOBREP are protected by copyright, with all rights reserved, unless otherwise indicated.